This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
Proteomics-based identification of potential lymphoma drug targets	<p>A proteomics assay could be useful for identifying new targets to treat lymphoma. In lymphoma-bearing mice, infusion of a biotinylating labeling agent identified proteins in the vasculature that are potentially accessible to systemic therapy. Isolation of the labeled proteins in combination with mass spectrometry identified bone marrow stromal cell antigen 2 (BST2; CD317) and 57 other proteins that were upregulated more than 10-fold in lymphoma-bearing mice compared with what was seen in normal mice. An anti-BST2 antibody inhibited tumor growth in mouse models of lymphoma compared with no treatment. Future studies could include validation of other upregulated proteins identified with the assay.</p> <p><i>SciBX</i> 2(46); doi:10.1038/scibx.2009.1708 Published online Dec. 3, 2009</p>	Patent and licensing status unavailable	<p>Schliemann, C. <i>et al. Blood</i>; published online Nov. 10, 2009; doi:10.1182/blood-2009-08-239004</p> <p>Contact: Christoph Roesli, The Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland e-mail: christoph.roesli@pharma.ethz.ch</p>